Claire E. Repellin

1.2k total citations
20 papers, 728 citations indexed

About

Claire E. Repellin is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Claire E. Repellin has authored 20 papers receiving a total of 728 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Molecular Biology, 7 papers in Oncology and 4 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Claire E. Repellin's work include TGF-β signaling in diseases (4 papers), Cancer-related gene regulation (4 papers) and CAR-T cell therapy research (3 papers). Claire E. Repellin is often cited by papers focused on TGF-β signaling in diseases (4 papers), Cancer-related gene regulation (4 papers) and CAR-T cell therapy research (3 papers). Claire E. Repellin collaborates with scholars based in United States, United Kingdom and Italy. Claire E. Repellin's co-authors include Mark C. Wilkes, Dalia Ercan, Marzia Capelletti, Pasi A. Jänne, Edward B. Leof, Tim Crook, Kwok‐Kin Wong, James G. Christensen, Kreshnik Zejnullahu and Paul J. Farrell and has published in prestigious journals such as PLoS ONE, Cancer Research and Oncogene.

In The Last Decade

Claire E. Repellin

20 papers receiving 719 citations

Peers

Claire E. Repellin
John D. Miedler United States
Emily Yun‐Chia Chang Canada
Jennifer A. Grabowsky United States
Christopher R. Shepard United States
Rachel V. Pearline United States
Marie-Pierre Podgorniak France
Yuwaraj Kadariya United States
Eleonora Sementino United States
Jiabo Di China
Christopher H. Chay United States
John D. Miedler United States
Claire E. Repellin
Citations per year, relative to Claire E. Repellin Claire E. Repellin (= 1×) peers John D. Miedler

Countries citing papers authored by Claire E. Repellin

Since Specialization
Citations

This map shows the geographic impact of Claire E. Repellin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Claire E. Repellin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Claire E. Repellin more than expected).

Fields of papers citing papers by Claire E. Repellin

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Claire E. Repellin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Claire E. Repellin. The network helps show where Claire E. Repellin may publish in the future.

Co-authorship network of co-authors of Claire E. Repellin

This figure shows the co-authorship network connecting the top 25 collaborators of Claire E. Repellin. A scholar is included among the top collaborators of Claire E. Repellin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Claire E. Repellin. Claire E. Repellin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Junttila, Melissa R., Claire E. Repellin, Jason E. Long, et al.. (2024). 62 (PB050): ORIC-114, a highly selective, brain penetrant EGFR and HER2 inhibitor, demonstrates best-in-class properties against Exon 20 insertions and other atypical EGFR mutations. European Journal of Cancer. 211. 114589–114589. 2 indexed citations
2.
Liu, Xiaohe, Thomas A. Shaler, Pauline Bourbon, et al.. (2022). Mega-High-Throughput Screening Platform for the Discovery of Biologically Relevant Sequence-Defined Non-Natural Polymers. ACS Central Science. 8(1). 86–101. 4 indexed citations
3.
Repellin, Claire E., et al.. (2021). NK‐Cell Biofactory as an Off‐the‐Shelf Cell‐based Vector for Targeted In Situ Synthesis of Engineered Proteins. Advanced Biology. 5(7). 6 indexed citations
4.
Repellin, Claire E., et al.. (2019). Engineered Ovarian Cancer Cell Lines for Validation of CAR T Cell Function. Advanced Biosystems. 4(1). e1900224–e1900224. 9 indexed citations
5.
Repellin, Claire E., et al.. (2018). Modular Antigen‐Specific T‐cell Biofactories for Calibrated In Vivo Synthesis of Engineered Proteins. Advanced Biosystems. 2(12). 10 indexed citations
6.
Kosaka, Takayuki, Junko Tanizaki, Raymond M. Paranal, et al.. (2017). Response Heterogeneity of EGFR and HER2 Exon 20 Insertions to Covalent EGFR and HER2 Inhibitors. Cancer Research. 77(10). 2712–2721. 100 indexed citations
7.
Wilkes, Mark C., Claire E. Repellin, & Kathleen M. Sakamoto. (2017). Beyond mRNA: The role of non-coding RNAs in normal and aberrant hematopoiesis. Molecular Genetics and Metabolism. 122(3). 28–38. 17 indexed citations
8.
Wilkes, Mark C., Claire E. Repellin, Jeong Han Kang, et al.. (2015). Sorting nexin 9 differentiates ligand-activated Smad3 from Smad2 for nuclear import and transforming growth factor β signaling. Molecular Biology of the Cell. 26(21). 3879–3891. 12 indexed citations
9.
Duramad, Omar, Béatrice Wang, Claire E. Repellin, et al.. (2014). Abstract 645: IGM-55.5, a novel monoclonal human recombinant IgM antibody with potent activity against B cell leukemia and lymphoma. Cancer Research. 74(19_Supplement). 645–645. 4 indexed citations
10.
Andrianifahanana, Mahefatiana, Mark C. Wilkes, Shiv K. Gupta, et al.. (2013). Profibrotic TGFβ responses require the cooperative action of PDGF and ErbB receptor tyrosine kinases. The FASEB Journal. 27(11). 4444–4454. 42 indexed citations
11.
Cortot, Alexis B., Claire E. Repellin, Takeshi Shimamura, et al.. (2012). Resistance to Irreversible EGF Receptor Tyrosine Kinase Inhibitors through a Multistep Mechanism Involving the IGF1R Pathway. Cancer Research. 73(2). 834–843. 163 indexed citations
12.
Andrianifahanana, Mahefatiana, Mark C. Wilkes, Claire E. Repellin, et al.. (2010). ERBB Receptor Activation Is Required for Profibrotic Responses to Transforming Growth Factor β. Cancer Research. 70(19). 7421–7430. 19 indexed citations
13.
Penheiter, Sumedha G., Raman Deep Singh, Claire E. Repellin, et al.. (2010). Type II Transforming Growth Factor-β Receptor Recycling Is Dependent upon the Clathrin Adaptor Protein Dab2. Molecular Biology of the Cell. 21(22). 4009–4019. 53 indexed citations
14.
Repellin, Claire E., Penelope M. Tsimbouri, Adrian Philbey, & Joanna B. Wilson. (2010). Lymphoid Hyperplasia and Lymphoma in Transgenic Mice Expressing the Small Non-Coding RNA, EBER1 of Epstein-Barr Virus. PLoS ONE. 5(2). e9092–e9092. 29 indexed citations
15.
Wilkes, Mark C., Claire E. Repellin, Min Hong, et al.. (2009). Erbin and the NF2 Tumor Suppressor Merlin Cooperatively Regulate Cell-Type-Specific Activation of PAK2 by TGF-β. Developmental Cell. 16(3). 433–444. 37 indexed citations
16.
Repellin, Claire E., et al.. (2004). Protease inhibitors prevent the protein kinase A-dependent loss of Rap1 GTPase from the particulate fraction of COS1 cells. Biochemical and Biophysical Research Communications. 315(4). 1077–1081. 6 indexed citations
17.
Sullivan, Alexandra, Martin Yuille, Claire E. Repellin, et al.. (2002). Concomitant inactivation of p53 and Chk2 in breast cancer. Oncogene. 21(9). 1316–1324. 67 indexed citations
18.
Reddy, A. Rama Mohan, Martin Yuille, Alice Sullivan, et al.. (2002). Analysis of CHK2 in vulval neoplasia. British Journal of Cancer. 86(5). 756–760. 30 indexed citations
19.
Gasco, Milena, Alex Sullivan, Claire E. Repellin, et al.. (2002). Coincident inactivation of 14-3-3σ and p16INK4a is an early event in vulval squamous neoplasia. Oncogene. 21(12). 1876–1881. 86 indexed citations
20.
Cumming, Sarah A., Claire E. Repellin, Maria G. McPhillips, et al.. (2002). The Human Papillomavirus Type 31 Late 3′ Untranslated Region Contains a Complex Bipartite Negative Regulatory Element. Journal of Virology. 76(12). 5993–6003. 32 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by John D. Miedler Breakdown of academic impact, for papers by Emily Yun‐Chia Chang Breakdown of academic impact, for papers by Jennifer A. Grabowsky Breakdown of academic impact, for papers by Christopher R. Shepard Breakdown of academic impact, for papers by Rachel V. Pearline Breakdown of academic impact, for papers by Marie-Pierre Podgorniak Breakdown of academic impact, for papers by Yuwaraj Kadariya Breakdown of academic impact, for papers by Eleonora Sementino Breakdown of academic impact, for papers by Jiabo Di Breakdown of academic impact, for papers by Christopher H. Chay
Rankless by CCL
2026